An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community


  • Potential conflict of interest: G.J.D. has received research support, is on the speaker's bureau, and is a member of an advisory board for Roche Pharmaceuticals. G.J.D. is also a consultant/advisor for Merck, Tibotec, and Abbott. J.G. is a member of an advisory board for Merck.

  • The Kirby Institute for infection and immunity in society is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. G.J.D. is supported by a National Health and Medical Research Council Practitioner Research Fellowship.

No abstract is available for this article.